Endoglin Controls Cell Migration and Composition of Focal AdhesionsBarbara A. Conley, Calvin Vary|Journal of Biological Chemistry|2004Cited by 127
Effect of Capivasertib in Patients With an <i>AKT1 E17K</i>-Mutated TumorKevin Kalinsky, Keith T. Flaherty, Larry Rubinstein et al.|JAMA Oncology|2020Cited by 106
Predictors of response and survival after concurrent chemotherapy and radiation for locally advanced squamous cell carcinomas of the head and neckMohan Suntharalingam, Barbara A. Conley, Michael L. Haas et al.|Cancer|2001Cited by 50
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trialAaron S. Mansfield, Keith T. Flaherty, Zihan Wei et al.|npj Precision Oncology|2022Cited by 42
Phase II Study of Erdafitinib in Patients With Tumors With <i>FGFR</i> Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1Jun Gong, Keith T. Flaherty, Alain C. Mita et al.|JCO Precision Oncology|2024Cited by 16